Medcura today said it moved its headquarters to a new purpose-built facility in Riverdale, Md.
The company chose the Discovery District of Riverdale, Md. to manufacture and commercialize its product line. Medcura plans to manufacture core cGMP compliant hemostatic and wound treatment materials at a manufacturing scale necessary to launch commercially.
“Expanding into this new plant is just the next stage in our growth arc,” CEO Larry Tiffany said in a news release. “These new headquarters give the company state-of-the-art manufacturing and R&D labs while providing a new corporate home where our growing team can build a successful business. By co-locating our product development and manufacturing, we can now more effectively integrate innovations in our chemistry, product design and means of delivery across our commercial product lines.”
The new manufacturing lab is over four times larger than Medcura’s prior footprint and has the strict isolation for manufacturing commercial materials.
“We’re thrilled that Medcura has joined a growing group of innovative and entrepreneurial companies that are creating jobs in multiple high-tech industries and are the foundation of our thriving Discovery District,” chief strategy officer for economic development at the University of Maryland Ken Ullman said. “Our goal is to foster the rapid growth of companies like Medcura that are started at the University of Maryland and mature to commercialize disruptive new technologies while helping to transform our community.”
